Switching from the original etanercept (the originator) to an etanercept biosimilar for rheumatoid arthritis (RA) – patients do just as well as those who remained on the originator.

Switching from the original etanercept (the originator) to an etanercept biosimilar for rheumatoid arthritis (RA) – patients do just as well as those who remained on the originator.

by | Jan 17, 2024 | Research, Study results

BSRBR-RA study blog BSRBR-RA Study website 🔗 Researchers: Lianne Kearsley-Fleet, Aasiyah Rokad, Man-Fung Tsoi, Sizheng Steven Zhao, Mark Lunt, Kath D. Watson, BSRBR-RA Contributors Group, Kimme L. Hyrich. What was already known? Etanercept is one of the main treatment...
The University of Manchester